Chronic lymphocytic leukaemia

The PBS subsidises idelalisib and obinutuzumab for patients with chronic lymphocytic leukaemia (CLL).

Idelalisib can be subsidised through the PBS under section 85 of the National Health Act 1953. Obinutuzumab can be subsidised through the PBS under section 100 of the National Health Act 1953. Idelalisib and Obinutuzumab are subsidised for patients with chronic lymphocytic leukaemia.

Section 100 arrangements for obinutuzumab

Obinutuzumab is available to a patient who is attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

and is a

  • day admitted patient
  • non-admitted patient, or
  • patient on discharge

The hospital name and provider number must be included on the application form. These items are not available as PBS benefits for inpatients of the hospital.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing idelalisib and obinutuzumab.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised idelalisib and obinutuzumab for the treatment of chronic lymphocytic leukaemia in writing and:

All applications for idelalisib must include a completed:

All applications for obinutuzumab must include a completed:

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 December 2017